Table 1 Participant characteristics.
Characteristica | No. (%) of patients with survey responses [n = 494] | No. (%) of patients who did not respond to the survey [n = 421] | Adjusted p value |
|---|---|---|---|
Race/ethnicity | <0.001 | ||
Non-Hispanic White | 423 (85.6) | 276 (65.6) | |
Asian/Pacific Islander | 7 (1.4) | 5 (1.2) | |
Black/African American | 44 (8.9) | 116 (27.6) | |
Hispanic | 12 (2.4) | 23 (5.5) | |
Personal history of cancer | <0.001 | ||
Other non-prostate cancers | 117 (23.7) | 39 (9.3) | |
No other non-prostate cancers | 352 (71.3) | 349 (82.9) | |
Family history of cancer | 0.011 | ||
Reported positive family history | 149 (30.2) | 85 (20.2) | |
No reported positive family history | 344 (69.6) | 336 (79.8) | |
Time of diagnosis | 1.0 | ||
Recent (≤1 year) | 219 (44.3) | 197 (46.8) | |
Not recent (>1 year) | 254 (51.4) | 207 (49.2) | |
Metastatic status at diagnosis | 1.0 | ||
Metastatic | 77 (15.6) | 79 (18.8) | |
Non-metastatic | 413 (83.6) | 337 (80.0) | |
Gleason (ISUP) Grade Group at diagnosis | 0.091 | ||
4 or 5 | 122 (24.7) | 137 (32.5) | |
3 or lower | 344 (69.6) | 253 (60.1) | |
Disease status at GGT | 1.0 | ||
Stable | 273 (55.3) | 207 (49.2) | |
Progressing | 57 (11.5) | 64 (15.2) | |
2019 NCCN® criteria | 0.475 | ||
Met criteria for GGT | 232 (47.0) | 229 (54.4) | |
Did not meet criteria for GGT | 262 (53.0) | 192 (45.6) | |
Germline status | 0.195 | ||
Positive | 55 (11.1) | 41 (9.7) | |
VUS-only | 218 (44.1) | 227 (53.9) | |
Negative | 221 (44.7) | 153 (36.3) |
